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Abstract
Corticotrophin Releasing Hormone (CRH) is a primary hormone in the fight or flight response targeting a
membrane bound G-protein coupled receptor (GPCR). Many people worldwide stand to benefit by the
development of CRH agonists and antagonists for the treatment of anxiety and depression, with
additional therapeutic targets including Alzheimer’s, pain and the prevention of premature birth: so why
the delay in development? In this review, we will discuss not only CRH, related proteins, receptors and
ligands, but some of the obstacles that have arisen, as well as strategies being pursued to overcome
these problems in the pursuit of this GPCR targeted therapeutic. Several key proteins influence the
complex and intrinsic regulation of CRH, including its receptors (CRHR), of which 3 types have been
categorised, CRHR1, CRHR2, CRHR3, each containing active and inactive splice variants. Additionally, the
CRH binding protein (CRHBP) is believed to moderate the effects of CRH at the receptor, whether it is as a
molecular mop, or a delivery vessel, or both, is still being investigated. Homology based receptor
modelling is a technique that has only recently become available with the crystallisation of bovine
rhodopsin (a GPCR),[1] and the application of this technique to the CRH receptors is still in the early
stages of development. Therefore, the medicinal chemist has previously had to rely on ligand-based
strategies, specifically, the development of pharmacophores. Thus, an extensive number of both CRH
peptide analogues and small ligands that show nanomolar antagonism have been developed with SAR
libraries being integral to the iterative drug design process.
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Abstract
Corticotrophin Releasing Hormone (CRH) is a primary hormone in the fight or flight
response targeting a membrane bound G-protein coupled receptor (GPCR). Many people
worldwide stand to benefit by the development of CRH agonists and antagonists for the
treatment of anxiety and depression, with additional therapeutic targets including
Alzheimer’s, pain and the prevention of premature birth: so why the delay in
development? In this review, we will discuss not only CRH, related proteins, receptors
and ligands, but some of the obstacles that have arisen, as well as strategies being
pursued to overcome these problems in the pursuit of this GPCR targeted therapeutic.
Several key proteins influence the complex and intrinsic regulation of CRH, including its
receptors (CRHR), of which 3 types have been categorised, CRHR1, CRHR2, CRHR3,
each containing active and inactive splice variants. Additionally, the CRH binding
protein (CRHBP) is believed to moderate the effects of CRH at the receptor, whether it is
as a molecular mop, or a delivery vessel, or both, is still being investigated.
Homology based receptor modelling is a technique that has only recently become
available with the crystallisation of bovine rhodopsin (a GPCR),[1] and the application of
this technique to the CRH receptors is still in the early stages of development. Therefore,
the medicinal chemist has previously had to rely on ligand-based strategies, specifically,
the development of pharmacophores. Thus, an extensive number of both CRH peptide
analogues and small ligands that show nanomolar antagonism have been developed with
SAR libraries being integral to the iterative drug design process.
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Introduction
There are approximately 800 different G-protein coupled receptors, GPCRs distributed
throughout the human body,[2] that are intrinsically involved in the control of the
majority of the bodies basic functions. They are the largest known family of signaltransducing molecules.[3] GPCRs are typified as membrane bound receptors, containing
seven highly conserved hydrophobic transmembrane α-helices, which coordinate to a
heterotrimeric G protein unit, thus deriving the name GPCR. In 1999 up to a quarter of
the top 100 selling drugs targeted GPCRs,[4] it has also been estimated that greater than
40% of all current drugs are targeted at GPCRs.[3] Therefore, the potential for drug
design and development targeting GPCRs is immense, despite it being currently notably
underdeveloped. This review focuses on the history of one example that has undergone
considerable development, corticotrophin releasing hormone (CRH) (also known as
corticotrophin releasing factor (CRF)), its GPCR, antagonists and agonists and their
relationship with regards to therapeutic intervention.

CRH
Corticotrophin Releasing Hormone (CRH) was isolated and characterised in 1981.[5-10]
It is a 41 amino acid polypeptide (Fig. 1a),[5-14] formed from the 196 amino acid CRH
precursor by the cleavage of the C-terminus.[5] The CRH peptide can be segmented into
three functional parts as shown in Fig. 1a. Residues 1-16 are believed to be important for
agonist binding and receptor activation.[15] Residues 17-31 contain the CRH-binding
protein binding (CRHBP) site and control the structural conformation of the protein,[15]
while 32-41 are vital for receptor binding.[15] The 3D structure of this peptide is not

fully established but is believed that the central section of the peptide is α-helical, and
that both terminal ends are relatively unstructured, however there is evidence that the Cterminus may form another α-helix, at least when bound to the receptor.[7, 16]
The CRH family of peptides and receptors has been identified in a large variety of
species, from mammals to fish and amphibians, but most importantly humans. CRH has
wide distribution throughout the CNS and periphery, including the reproductive
system.[9, 10, 12] CRH is the key regulator of the hypothalamus-pituitary-adrenal (HPA)
axis.[6, 8, 9, 13] The HPA axis influences a multitude of vital bodily functions, the
driving force being the variety of stress responses. Therefore the systems influenced by
alterations in CRH encompass a large and diverse cross section including cardiovascular
regulation, respiration, appetite control, glucose metabolism, immune function, cognitive
and motor behaviour, and reproduction. It is through the interaction of CRH with its
receptors that it elicits these effects. With such widespread influences throughout the
body, it is logical that any imbalances or errors within the system are attributed or
connected to a multitude of disorders. Some that are discussed later include
neurodegeneration, anxiety, depression, and Alzheimer’s disease.

Figure 1: (a) The CRH peptide, showing the various binding regions of the peptide. (b)
The CRH receptor 1 (CRHR1), the extracellular domain (ECD), transmembrane domain

(TMD), and intracellular domain (ICD). The peptide binding (determined from NMR
binding and mutation studies), non-peptide binding sites and G-protein binding sites are
also highlighted. Note the NMR binding studies were performed on CRHR2 but have
been extrapolated here for diagrammatic purposes.[14, 17-19]
CRH Receptor (CRHR)
The CRH receptor is a membrane bound G-protein coupled receptor (GPCRs) (Fig (1b)),
subclass B,[5, 7, 13, 16, 20] distributed throughout the brain and the periphery. Class B
G-proteins are a unique class of G-protein known as the secretin-vasointestinal
peptides;[3] there are 15 known receptors in this class.[16] GPCRs are categorised by
their nucleotide and amino-acid sequence homology, native ligands, genes, and Nterminus.[3, 21] Class B specifically are activated by neuropeptides and peptide
hormones.[3] Included in the class B GPCRs are calcitonin, parathyroid hormone,
glucagon-like peptide, and GHRH, some of the applications, current and potential include
osteoporosis and Type II diabetes.[16, 22]
There are three types of CRH receptors that have been identified. CRHR1 and 2 share 70%
homology on the amino acid level and are coded for by separate genes.[19, 23] The
general structure of a CRHR and GPCRs in general consists of a N-terminus and 3 loops
in the extracellular domain (ECD), 7 hydrophobic α-helical transmembrane domains
(TMD), and 3 loops and the C-terminus in the intracellular domain (ICD) (Fig (1b)).[16]
The ECD region is the initial region for ligand binding and possesses the greatest
variation between the receptor subtypes.[23] The N-terminus region has only 40%
homology between CRHR1 and CRHR2. The TMD and ICD regions have greater than

80% homology, while the third IC loop is identical between all CRH receptors and is
responsible for the G-protein interaction, as highlighted in Fig (1).[5, 7, 20]

CRHR1
Primarily found in the brain,[5, 6, 11, 12] CRHR1 is composed of 415 amino acids (α
splice variant). It has 8 variants; α, β, c, d, e, f, g, h, however α is believed to be the only
active form.[20, 23]
From mutant and chimera studies of CRHR1, it has been shown that the N-terminus
controls peptide ligand binding to the receptor [7, 11, 24] by binding to the C-terminus of
the ligand. The ECD1 and 3 and the ECD2-TMD5 junction are also believed to be
involved in binding.[7, 14, 18, 19] It is believed that the N-terminus of CRH also binds
the TMD with weak affinity and it is this interaction that is responsible for activation of
the receptor, however specific residues/domains for this interaction are not known.
Mutation studies exchanging residues His199 (TMD3) and Met276 (TMD5) of CRHR1
with residues from CRHR2 showed 100 fold decrease in affinity for the non-peptide
antagonist NBI 27914; thus it has been postulated that TMD3 and 5 are responsible for
non-peptide ligand binding.[7, 19] Therefore, the extracellular domain being responsible
for the initial peptide binding and non-peptide ligands are inserted into the membrane
bound helix bundle.[7]
CRHR1 is the primary receptor responsible for the normal responses to stress; it is the
primary receptor for CRH and thus a key regulator of the HPA axis. Therefore, it plays an
integral role in an array of processes, making it a major target for CRH antagonist
therapeutic intervention.

CRHR2
Unlike CRHR1, CRHR2 has three active variants, α, β, γ. The α and β versions are larger,
consisting of 411-413 and 413-438 amino residues respectively, and are found throughout
the CNS and the periphery, while γ is only 397 amino acids in length and found only in
humans solely in the brain.[6, 9, 11, 24]
While CRHR1 is involved in the normal response to stress, it is believed that CRHR2 is
involved in the fine-tuning of these responses, it regulating the peripheral stress
responses, such as metabolism, vasculature, and muscular responses. It also appears to
counteract much of the CRHR1 responses, possibly in a regulatory role to avoid over
stimulation.
In 2004 a proposed 3D structure of the mouse CRHR2β N-terminus region was published
based upon NMR structure studies.[17] They concluded that there were two pairs of
antiparallel β-sheets and three conserved disulfide bonds that construct the tertiary
assembly of the N-terminus. Also identified were amino acid residues that appear to be
integral in peptide ligand binding, which were compared to those already identified
through mutagenesis studies. This tertiary structure has also been demonstrated for
CRHR1.[16, 25]

CRHR3
CRHR3 is the newest of the CRH family of receptors identified and thus far has only been
identified in the catfish.[5, 12, 23, 26] It is notably similar to CRHR1 and CRHR2 with
sequence homology of 85% and 80% respectively.[26] As it has not been identified in

humans and thus is not a potential therapeutic target, it shall not be further examined in
this review.
Table 1 summarises the properties, location role and the natural ligands that bind to the
CRH receptors and the CRHBP.

Table 1: Comparison of the properties of the peptides that bind CRH; CRHR1, 2,

3

and

CRHBP.
A. A.

Primary

Ligand

Variants
length

Role
Location

Binding
Regulate
CRH, Urocortin

415(α),
CRHR1
(145-444)

α−h

Brain and

the stress
I, Sauvagine,

pituitary

responses
Urotensin
(HPA axis)
Homeostasi

CNS,
411(α),
CRHR2
(397-431)

Urocortin I-III,

s/fine

Sauvagine,

tuning of

Urotensin

stress

periphery,
α−γ

brain, heart,
vasculature
response

CRHR3

428

-

Catfish brain

CRH

CRH

CRH,
Circulation,
CRHBP

322

-

storage,
Urocortin,

brain

delivery,
Urotensin I
clearance

CRH Binding Protein (CRHBP)
Binding proteins (BPs) have been reported for a growing number of hormones throughout
the body. Hormones such as insulin-like growth factor-I (IGF-I) and growth hormone
have BPs believed to play an essential role in the action and regulation of these
hormones.[27] Associated with all CRH function is a CRH binding protein (CRHBP).
This water-soluble free protein is 37 kDa in size [11, 20, 27] and consists of 322 amino
acid residues [6, 8] and is therefore smaller than the receptors. CRHBP has been
identified in both mammalian and non-mammalian vertebrates, including humans, mice,
rats, sheep, fish, amphibians (frogs), and birds.[27] The binding protein is highly
conserved between species, with 321-324 amino acids across all species.[27] It is highly
conserved with 85% homology between human and rat CRHBP [8] and it has been
suggested that it is a phylogenetically ancient protein with extensive structural and
functional conservation.[27]
Human CRHBP is distributed in plasma, amniotic fluid, synovial fluid, placenta,
pituitary, and brain.[27] Rodent and ovine CRHBP however, has not been found in the
plasma and in these species CRH mRNA has only been identified in the brain and
pituitary.[27] CRH and CRHBP are both expressed in many common regions within the
brain, as is the CRHR and CRHBP.[27]
There are 10 cysteine residues located in the protein that form 5 consecutive disulfide
loops when folded, and are essential for binding CRH.[27, 28] The greatest sequence
diversity is found at the two terminus ends,[27] leaving the core of the BP (residues 40300) with a high sequence homology of 73% across the species; human, rat, mouse,
sheep and frog.

In contrast to the receptors of CRH, the non-membrane bound CRHBP is found
throughout the plasma and the CNS, and has 10 fold higher affinity for CRH compared to
the receptors.[6, 29] It is estimated that between 60-90% of total CRH in the human brain
is complexed with the BP.[29] Investigations into the affinity of various fragments of
hCRH or related peptides for CRHBP indicate that residues 9-28 are crucial for ligand
binding.[30]
Currently the function of the BP is poorly understood. It is theorised that the binding
protein acts as a buffer to regulate the concentration of free CRH and CRH-like peptides,
and thus their influence upon the HPA axis.[6, 27] An additional theory is that the
binding protein may assist in the clearance of CRH from the body,[27] while yet another
suggests that it may act as a CRH transport complex, protecting it (and like peptides)
from degradation and assisting in delivery.[27] A further theory is that CRHBP may have
its own membrane bound receptor and is mostly associated with the membrane and not
free, but this is as yet unsubstantiated.[27, 31] Adding to the debate regarding the
function of the BP, is the frog CRHBP, identified as a thyroid-associated hormone
connected to the metamorphic phase of tadpole maturation to frog.[27, 32] In summary,
the role and function of the CRHBP is not yet fully understood.

Receptor Binding and Signalling
Activation of the CRH signalling pathway can be divided into two areas; receptor binding
and pathway signalling. A hypothesis was proposed for the mechanism of binding for
class B GPCRs by peptide agonists (such as CRH) involving a two-domain process (Fig
(2)).[7, 15-17, 22] The N-terminus of the receptor initially binds the carboxyl terminus of

the peptide; this then initiates rearrangement of the receptor with the insertion of the
peptide agonist amino terminus into the transmembrane helix bundle and activation of the
receptor (Fig. (2), Step 1 and insert).[13, 16, 17]
The CRHR in the activated form binds the G-protein: guanine nucleotide stimulatory
proteins (Gs) (Step 2, Fig. (2)). Gs a heterotrimeric G-protein, consists of three subunits,
Gα-Gβ-Gγ, and at least 28 different Gα subunits have been identified.[21]
The G-protein trimer is associated with the inactive GDP. Upon interaction with an
activated receptor, the GDP is converted to GTP and binds to the Gα subunit (Fig. (2),
step 3), the Gα-GTP complex then dissociates from Gβ-Gγ and the separated parts proceed
to activate a multitude of different 2nd messenger pathways (Fig. (2), step 4).[21] One
point to note is that receptors do not have to be activated for coupling with G-proteins,
and this coupling can in fact promote ligand binding.[16, 17]
Non-peptide CRH ligands (antagonists), have a different binding mode to the peptide
ligands. It appears that the small molecules have no interaction with the ECD, but insert
themselves directly into the TM domain (Fig. (1)), specifically shown to have affinity for
residues 199 and 276 in TM2 and TM5 respectively.[7, 19] After insertion of the nonpeptide ligand into the helix bundle, the ligand allosterically blocks the 2nd domain
insertion of the peptide ligand binding, thus acting as antagonists to CRH and its
associated ligands.[13, 16, 17]

Figure 2: The CRH signalling/binding cycle. Details of the step-wise binding and
activation of the CRH peptides are shown, including the 2 domain binding model.[16]
Therefore, the signalling from the activated receptor and G-protein initiates the G-protein
activation stimulation of adenyl cyclase that in turn activates protein kinase A (PKA) and
other cAMP pathways. They can stimulate adrenocorticotrophin (ACTH), β-endorphin
and other proopiomelanocortin related peptides from the anterior pituitary,[8] protein
kinase C (PKC), protein kinase B/Akt, p44/p42 and p38 mitogen-activated protein kinase
(MAPK), intracellular Ca2+, nitric oxide synthase, guanylate cyclase, prostaglandins,
steroidogenic enzymes, FasL production and apoptosis.[12, 33] As a result the activation

of the CRH receptor has a multitude of different potential influences upon cells that are
intrinsic to cellular, and bodily functions.

Natural Ligands
CRH is the endogenous ligand for the CRH receptors, however over time an increasing
number of natural ligands have been identified for CRHR1 and CRHR2. At least five
CRH-like agonist ligands have been recognised across a variety of species, Urocortin I,
II, III, Urotensin I, and Sauvagine (Table 2).
Urocortin I, II and III have been identified in numerous species (Table 2), from mammals
to fish.[5] Urocortin I was discovered in 1995, followed by II and III in 2001,[34, 35]
these three peptides may share the same name but they have very different binding
affinities. Urocortin I is non-selective between the CRH receptors, slightly favouring
CRHR1, while Urocortin II and III are selective for CRHR2.[15] It has been theorised that
CRH is the endogenous ligand for CRHR1 and Urocortin is the endogenous ligands for
CRHR2 (particularly II and III).[7] Both Urocortin II and III seem to influence appetite,
acting as a suppressant rather than playing a role in the stress response,[34] and Urocortin
III has been linked to glucagon and insulin secretion.[35] Human Urocortin II, also
known as Stresscopin has been identified from the human genome, however it appears to
lack the processing genes to produce it, there is conjecture as to the entire identity of this
gene.
Initially identified in fish, Urotensin I has since also been identified in mammals. Similar
to CRH, it is a 41 amino acid peptide chain but is reported to only share 50% homology

(Table 2). Urotensin is a non-specific ligand with high affinity for CRHR1 and CRHR2,
but uniquely has little affinity for the BP.[29]
Sauvagine is a linear amphibian ligand of 40 amino acid length.[36] While being highly
potent for both CRH receptors it does bind with higher affinity to CRHR2, it is 5-10 times
more potent for these receptors than CRH.[6, 8, 37] It has been suggested that there is
still a sauvagine like ligand in mammals that is yet to be discovered that would be the
native ligand for CRHR2 rather than Urocortin.[38]
The only CRHR1 selective natural ligand identified is ovine CRH (oCRH). Table 2 shows
all other ligands possessing good affinity for both or favour CRHR2 binding.[15, 39]
While not found in humans, this ligand has the closest homology to CRH, therefore it
potentially provides a useful tool for investigating both receptor locations and for refining
our understanding of the differences in ligand-receptor interaction for the two CRH
receptors.

Table 2: Comparison of CRH and other natural ligands and their receptor selectivity. The
oCRH is the only peptide selective for CRHR1, Urocortin II and III are selective for
CRHR2, there is no peptide selective for only the BP. Human=h, rodent=r, ovine=o,
amphibian=a, fish=f [5, 30, 35, 39]
Binding Affinity
A.A.
% Homology
Ligand
Animal
Residues
to hCRH
CRHR1 CRHR2 CRHBP
hCRH

h

41

100

High

Medium

High

oCRH

o

41

83

High

Low

Low

Sauvagine

a

40

48

High

High

Medium

Urocortin I

r, h, o

40

44

High

High

High

Urocortin II

h, r, f

38

34

Low

High

High

Urocortin III

h, r, f

38

30

Low

High

Low

Urotensin

f

41

50

High

High

Low

CRH in Disease and Therapeutic Application
CRH has a broad spectrum of influences upon the human body and therefore has direct
implications for the intervention in a wide-ranging number of disease states. For example,
one of the many side effects of HIV-1 infection is neurodegeneration. This condition has
been largely attributed to increased activation of the HPA axis. It is believed the HIV
viral coat protein gp120 acts at the hypothalamic paraventricular nucleus (PVN) to
stimulate CRH and arginine vasopressin (AVP) production and thus stimulation of the
HPA.[40]
There are multiple neurological diseases proposed as potential drug targets for CRH
agonists and antagonists including anxiety, depression, Alzheimer’s disease, and post
traumatic stress disorder, to name a few.[41-44]
It has been proposed from rat models that a CRHR2 agonist may serve as an anxiety
therapeutic. In contrast to CRHR1 that induces anxiogenic properties, CRHR2 was found
to stimulate anxiolytic properties. By targeting CRHR2 for anxiety, it has been suggested
that side effects would be minimised due to the few known biological roles it plays in
control of the body’s equilibrium.[41] It has also been suggested that CRHR1 antagonists

would also have low side effects with respect to the treatment of depression. CRHR1
antagonists have been found to exert their effect only during high stress situations, when
the HPA axis and CRH are activated.[42] Thus, it is expected that these antagonists
would have minimal effects and would be observed only during stress.
During high chronic stress situations, cortisol levels are elevated for prolonged periods.
Cortisol is believed to be toxic to neurons with long-term exposure and the damage
caused is believed to impair the ability to form memories thus inducing post-traumatic
stress disorder. As CRH is one of the primary stimulating hormones in the production of
cortisol, a CRH antagonist is a potential treatment to assist in the recovery from
trauma.[43]
Alzheimer’s disease (AD) is typically characterised by the formation of the destructive
amyloid β-peptide,[44] and decreased levels of CRH in CSF fluid.[29, 43] It is reported
that CRH prevents cell death caused by amyloid β-peptide and thus could slow or prevent
the onset of Alzheimer’s disease.[44] Ligands capable of displacing CRH from its
binding protein, thus increasing free CRH, may have potential therapeutic application and
have been shown to increase spatial learning and memory in rats.[29, 44]
The CenterWatch Drugs in Clinical Trials Database (USA) reports four CRH related
drugs have recently reached clinical trials;[45] two are peptide-based whilst the other two
are non-peptide small molecules. Xerecept, which is the trade name for the synthetic
preparation of CRH, is the most advanced, reaching phase III trial in 2004. It is to be
tested for the treatment of peritumoral cerebral oedema resultant from brain tumours
(brain swelling due to brain tumours), utilising the vasoconstrictive properties of CRH
after trauma injury.[45] Urocortin II a CRHR2 selective agonist was placed in phase I

clinical trials in 2004 for the treatment of congestive heart failure. It exhibits hypotensive
and anxiolytic effects via CRHR2, and is located in the cardiovascular system, and is
expected to move into phase II early in 2005. There are reports (2002-3) of 2 separate
CRHR1 non-peptide antagonist in phase I clinical trials for depression and anxiety, NBI34041 and SB723620 (NBI-37582) although the outcome of these trials is unclear.[45]
N
N N
N
N
N

Figure 3: CRHR1 non-peptide antagonist R121919 (NBI 30775) underwent phase II
clinical trials in 1999.

Phase II clinical trials were carried out on the CRHR1 antagonist R121919 (NBI 30775),
shown in Figure (3), a water-soluble pyrazolopyrimidine,[46] as an antidepressant in
1999. The results of the 24 patient trial appear to be positive for CRH antagonists as
viable antidepressants. The drug showed an improvement in the symptoms of depression
and an increase again at the cessation of treatment.[47] Weight gain and leptin levels
were also monitored due to the known role of CRH in weight control and no effect was
observed.[48] Although not definitive, R121919 also presented some evidence of
stabilising effects on sleep patterns of major depressive patients.[49] Liver toxicity was
observed at high dosages of R121919, reversible elevations of liver enzymes were
observed in a parallel study with healthy controls, thus halting all further testing with
R121919.[46, 50] It was concluded that CRHR1 was a promising antidepressant target,

with minimal side effects observed, and the liver toxicity is believed to be a result of that
specific compound and not the mechanism of action;[50] thus other CRHR1 are not
expected to show such toxicity. It is worth noting that no placebo was used in the
trial.[16]

CRH Therapeutics Patents 2000-2005
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25

Non-peptide
Antagonists

20

Peptide
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Year
Figure 4: Non-Peptide and Peptide agonist and antagonist patents published since 2000.
(* As of 11th May 2005.)

Since 2000, numerous patents have been published for potential CRH targeted
therapeutics (Fig (4)). The majority of these have been targeted at CRHR1 and in
particular non-peptide antagonists. The year 2004 was the most prolific year thus far for
non-peptide CRH antagonist patents; unfortunately, the consistent turnover of
compounds/patents (over 100 since the year 2000) still has not seen a successful
therapeutic reach the market.

Antagonists Drug Design for CRH
As CRH targets a GPCR, it presents a difficult challenge to design selective receptor
antagonists. Several techniques have been adopted in an attempt to develop highly active,
specific and novel antagonists for this drug target. There are two types of antagonists,
peptide and non-peptide, both types have had compounds reach at least phase I clinical
trials and are relevant potential therapeutics.
The peptide antagonists are largely based upon the natural ligands of the CRH receptors.
The main advantage of this type of antagonist is its ability to mimic the endogenous
ligand and integrate into the body’s systems. They have been developed from structureactivity relationships (SAR), mutant, chimeric, and substitution studies.
Non-peptide antagonists have also been extensively published. Considering the little
information known about the receptor-binding site for these compounds, work in this area
has been successful with numerous sub-nanomolar affinity compounds published over the
last 10 years. These compounds have been developed initially using library screening and
now in combination with SAR work.[6-10, 51-53]
Peptide Antagonists
All of the non-natural peptide ligands, both agonists and antagonists, have been
developed from SAR work and derivatisation of the natural ligands. A large variety of
alterations from chain shortening/lengthening, residue substitution, methylation,
acylation, radiolabelling, cyclisation, and confinement to helical configuration (via a
lactam bridge), have been performed in an attempt to develop new, more potent ligands.
The potential for CRH to form a helix at the C-terminal, theorised to be the active form of
CRH, was the motivation for the development of the α-hel-CRH(9-41),[7] the first CRH

antagonist developed.[54] A more active derivative, astressin, {cyclo(30-33)-[DPhe12,
Nle21,38, Glu30, Lys33]r/h CRH12-41} is also α-helical, utilising a lactam ring to constrain
the peptide and is reported to be about 32 times more potent than α-hel-CRH(9-41) (Table
3) for CRHR1.[54] It is believed that astressin may have neuroprotective properties that
would be useful in treating ischemic damage.[55] Interesting to note is the inverse
affinity these ligands have for the binding protein.
Most of the peptide antagonists developed have been synthesised from natural ligands
with shortening of the N-terminus region. This supports the hypothesis previously
discussed,[17] that ligand binding occurs in a two-step model with the carboxyl terminus
of the ligand binding, and then the amino terminus inserting into the transmembrane
domain to activate the receptor. The absence of the amino terminus end of the antagonists
means inability to initiate the activation of the receptor but effectively blocks the
endogenous ligand from binding the receptor.[16, 17]
Numerous CRH natural ligands have now been radiolabelled. Human and ovine CRH,
Urocortin and Sauvagine have all been labelled with

125

I and used in radio assays to

investigate receptor distribution, antagonist binding and ligand receptor interactions.[5658] Urocortin has also been labelled with tritium.[57] All of the radiolabelled compounds
have reported minimal effects on binding and appear to be useful tools in investigating
this complex hormonal system.

Table 3: Receptor affinity (IC50 (nM)) of human CRH and Sauvagine, both of which are
native CRH ligands, and comparison with some synthesised peptide antagonists. NB: no
binding observed (to rCRHBP).[39, 59]

CRHR1

CRHR2

CRHBP

hCRH

1.6

42

0.54

Sauvagine

0.52

0.92

57

α-hel-CRH

61

4.3

1

Anti-sauv-30

370

0.30

NB

astressin

11

5.2

90

CRHR1 and 2 are not the only targets for CRH related antagonists. The CRHBP has not
been as widely targeted however, at least one patent for peptide and/or non-peptide
antagonists was published in 1996.[31] The therapeutic is for the treatment of
Alzheimer’s disease utilising a CRHBP antagonist, with the premise to block CRH from
the BP thus increasing the levels of free CRH as described.[31] Ligands such as hCRH(633) have been designed with high specificity for binding to the CRHBP over CRHR.[27,
30] For example, a comparison of the CRF-BP ligand inhibitor, r/hCRF(6-33) with CRH
in mice and rats showed a reduced food uptake observed in mice.[60]

Non-Peptide Antagonists
In 1991 the first CRH non-peptide antagonist patent was published describing a series of
pyrazolones.[6, 9] The progression from then was slow until 1996,[61-63] but
subsequently hundreds of CRH non-peptide antagonists have been published. Despite the
great number of these compounds, none have made it onto the pharmaceutical market. A
possible explanation of this can be shown by a timeline of antagonist development
(Figure (5)). Until 2002, only two structural scaffolds had emerged, derivatives of those

developed in 1996. From 2002 onwards a much greater diversification has occurred
accompanied by further derivatisation and optimisation of the current scaffolds, but no
clearly successful drugs. The need is evident for new structural diversification if a drug is
to be developed due to the problems that are plaguing the current leads.
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Figure 5: Timeline depicting examples of published non-peptide CRH antagonist
development.[6, 61, 62, 64-84]

Although biological activity is prominent, with many sub-nanomolar derivatives
available, substantial problems prevail and include poor bioavailability, toxicity, lack of
structural diversity, and potentially low specificity (high receptor distribution) and thus
high possibility of side effects.[16, 85]
Solubility is a considerable issue with CRH non-peptide antagonists. The hydrophobic
nature of both the membrane bound GPCRs and the hypothesised binding domain within
the transmembrane region means that antagonists need to be largely hydrophobic - the
majority have a calculated LogP (clogP) (octanol-water partition coefficient) greater than
3. With such hydrophobic compounds, the most difficult challenge is maintaining
reasonable bioavailability to ensure they dissolve into the circulatory system and are also
able to cross the blood brain barrier (the primary target for most potential applications).
Thus far, in an attempt to overcome these difficult problems, attention has turned to
increasing the number of heteroatoms, particularly in the aromatic rings and utilised
ionisable derivatives.
As discussed previously toxicity has been a problem for at least one non-peptide
antagonist, R121919. While this toxicity is believed to be independent from the
compounds mode of action at the receptor and thus not likely to extend to other
antagonists, this is still yet to be confirmed in human trials. This liver toxicity was also
only observed at high doses.[50]
CRH is still a relatively new drug target (of the last 10 years) and as relatively little detail
is known of GPCRs and specifically the CRH receptor binding site, this poses a difficult
therapeutic target for drug design and development. As a result, there is little structural
diversity contained within small ligand antagonists leading to a restriction on available

information but has allowed for detailed SAR of the compounds. Figure (6) shows some
examples of the molecules and the three key regions required for activity for the small
molecule antagonists of CRHR1, (A), (B), (C). The lower region, (A), is the most highly
conserved and is a substituted aromatic moiety, mostly with a 2,4 or 2,4,6 substitution
pattern. It is believed that this ring is angled into the plane in comparison to section
(B).[7, 9, 10, 78] The middle region (Fig. (6) (B)) consists of a 5 or 6 atom aromatic
heterocyclic core and has become diversified in recent years with the most widely
investigated being the pyrimidine based core structures;[65] these rings can be fused to
additional rings,[62, 86] have additional heteroatoms, and there has also been examples
with 5 membered rings and linear conjugated heteroatoms.[71, 72] It appears most
importantly for this region that one of the heteroatoms is a nitrogen (H-bond acceptor)
and is located 2-3 bonds away from the aromatic ring of region (A). The third region
(Fig. (6) (C)) is the most diversified region, the only consistency maintained being its
hydrophobic nature. Many of the substituents in this region connect to region (B) via a
weakly basic tertiary amine.
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Figure 6: Structure-activity relationships for CRH non-peptide antagonist. There are
three regions (A, B, and C) that is necessary to consider.[61, 71, 73, 87]

The potential side effects due to the wide spread action and location of CRH receptors is
a relevant issue. From the clinical trial of R121919, it appears that CRHR1 antagonists are
promising drugs with little if any side effects.[47-50] From the reports, the drugs had no
adverse effects on hormonal systems (including the HPA axis),[50] weight gain [48] or
sleep patterns, if anything stabilised them to normal at the higher doses.[49] This little
influence on the multitude of homeostatic systems regulated by CRH can be attributed to
three key points. The CRH systems are highly controlled with negative feedback and
backup systems in place to minimise disturbances; it has been shown that there is no
effect on the HPA system in rodents under normal conditions.[20] The CRHR1 is located
in the brain and pituitary and does not directly influence the body’s periphery, thus
eliminates those side effects. Finally CRH has the greatest influence on the bodies
homeostasis when stressed, and therefore non-peptide antagonists are unlikely to exhibit
much influence except under stressed conditions; this theory has been tested in
rodents.[20]
As noted earlier, antagonists of the CRHBP could have potential applications for treating
Alzheimer’s disease. Currently there is only one patent for non-peptide CRHBP
antagonists published, WO9851312.[88] These compounds are thiadiazinedione dioxides,
Figure (7), are structurally unique to any of the other CRH non-peptide antagonists and
reportedly increase levels of free CRH in the brain. Further information describing these
molecules as therapeutics is not reported.
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Figure 7: CRHBP non-peptide antagonists for the treatment of Alzheimer’s disease. R1,
R1a = alkyl, arylalkenyl, furylalkenyl, thienylalkenyl, pyrrolylalkenyl. A = S, NH,
monocyclic or bicyclic heterocyclic group containing 1 or more nitrogen atoms in which
A is bound through a nitrogen atom. R2 = H, alkyl, cycloalkyl, aryl

The Future of Drug Design Development for CRH
SAR has been the most successful technique to date for targeting this specific GPCR, for
both peptide and non-peptide antagonists. While the peptide agonists and antagonists
have had some success through SAR studies and development, it is the small molecule
non-peptide antagonists that are of most interest as potential therapeutics. There has been
a greater structural diversification in recent years of these compounds, however it has
proven elusive to combine good pharmacokinetics with good activity. With the increasing
demand to diversify the structural basis of the antagonists, alternative techniques are
being pursued.
Due to the absence of a definitive 3D structure of a GPCR until recently, computer–aided
ligand based design has been one of the few tools available to medicinal chemists.
Limited ligand-based pharmacophore work has been published for CRH.[85], [89]
Ligand-activity pharmacophores are a 3D representation of the theorised key elements in
receptor-ligand interaction extrapolated from correlations between known structure and

activity data. This work confirmed the hydrophobic nature of the molecules and the
importance of a hydrogen bond acceptor and the angular positioning of the aromatic ring
to the heterocyclic core. There have been significant limitations in applying computeraided pharmacophore development programs until recently; while these hypothesis were
able to predict good activity they gave a large number of false positives as they were
unable to consider any negative steric interactions.
With the elucidation of the first GPCR (rhodopsin) to be crystallised,[1, 90, 91]
homology modelling has come to the forefront as the leading technique for GPCR based
drug design, and is under investigation for it’s application to CRH. At this stage it has
limitations; Rhodopsin itself is a class A member of the GPCR superfamily while CRH is
class B,[21] these two classes of GPCRs differ in amino acid and gene sequence,
mechanism of activation and types of activators, and initial sequence alignment
comparisons. Comparison of the two receptors show that the key binding domains for
peptides of the receptors appear to be significantly longer in length for CRH [7] and are
also positioned in the most flexible regions (N-terminus and ECD). The recent
publication of the NMR structure of the N-terminus greatly assists in the understanding
of these differences.[17] Additionally, observations of the molecular structure of the nonpeptide antagonists of both classes of GPCR would suggest unique and independent
binding domains. Class A molecules display an array of potential ligand-receptor
interactions while the class B CRH molecules suggest largely hydrophobic
interactions.[16] This method offers enormous possibilities for the future development in
drug design for CRH, however, it still has many obstacles to overcome.

Therapeutic Application and Limitations
It would appear that the evolution of CRH as a therapeutic target is entering an exciting
stage in its development. The non-peptide antagonist, R121919, and a number of others,
reaching clinical trials, has legitimised this target as a very viable and promising area of
research, particularly in the area of depression.
Although peptide agonists and antagonists have numerous applications as potential
therapeutics, significant limitations exist including the crossing of membrane barriers
(particularly the blood brain barrier), and peptide metabolism, both integral for
therapeutic application. These limitations are reflected by the lower number of patent
applications.
The far more lucrative non-peptide antagonists continue to give hope to the rise of
potential therapeutic. Finally with diversification of the core units and improving
solubility it appears that soon a break-through compound capable of balancing the
hydrophobic nature of the receptor binding site and the hydrophilic demands of
bioavailability might soon be attained.
CRH related diseases are very broad and varied. Although the distinction between the
receptors and their vastly different signalling and effects is clearly defined, the possibility
of such an influential target not having wide ranging side effects must be carefully
examined. The intricacy and complexity of CRH signalling and the HPA axis may afford
a solution to this or compound the problem. The HPA axis has numerous feed-back and
backup utilities in place designed to minimise any disturbance to the body’s homeostasis.
From the various knockout mice created we can observe that they are all viable and often
no side effects are observed unless under stressed conditions, when the majority of the

applications of the drugs would be desired. Despite these aspects, the expectation that
therapeutics based on CRH antagonists and agonist will soon emerge is high.
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